Association between pathologic response and survival after neoadjuvant therapy in lung cancer

被引：86

作者：

Deutsch, Julie Stein ^{[1
]}

Cimino-Mathews, Ashley ^{[1
]}

Thompson, Elizabeth ^{[1
]}

Provencio, Mariano ^{[2
]}

Forde, Patrick M. ^{[1
]}

Spicer, Jonathan ^{[3
]}

Girard, Nicolas ^{[4
]}

Wang, Daphne ^{[1
]}

Anders, Robert A. ^{[1
]}

Gabrielson, Edward ^{[1
]}

Illei, Peter ^{[1
]}

Jedrych, Jaroslaw ^{[1
]}

Danilovae, Ludmila ^{[1
]}

Sunshinee, Joel ^{[1
]}

Kerr, Keith M. ^{[5
]}

Tran, Mia ^{[6
]}

Bushong, Judith ^{[6
]}

Cai, Junliang ^{[6
]}

Devas, Vipul ^{[6
]}

Neely, Jaclyn ^{[6
]}

Balli, David ^{[6
]}

Cottrell, Tricia R. ^{[7
]}

Barase, Alex S. ^{[1
]}

Taube, Janis M. ^{[1
,8
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD 21218 USA

[2] Hosp Univ Puerta de Hierro, Madrid, Spain

[3] McGill Univ, Hlth Ctr, Montreal, PQ, Canada

[4] Inst Curie, Inst Thorax Curie Montsouris, Paris, France

[5] Aberdeen Royal Infirm, Aberdeen, Scotland

[6] Bristol Myers Squibb, Princeton, NJ USA

[7] Queens Univ, Kingston, ON, Canada

[8] Johns Hopkins Univ, Sch Med, Mark Fdn Ctr Adv Genom & Imaging, Baltimore, MD 21218 USA

来源：

NATURE MEDICINE | 2024年 / 30卷 / 01期

关键词：

END-POINTS; CELL; CHEMOTHERAPY; REGRESSION; CARCINOMA; CRITERIA;

D O I：

10.1038/s41591-023-02660-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Neoadjuvant immunotherapy plus chemotherapy improves event-free survival (EFS) and pathologic complete response (0% residual viable tumor (RVT) in primary tumor (PT) and lymph nodes (LNs)), and is approved for treatment of resectable lung cancer. Pathologic response assessment after neoadjuvant therapy is the potential analog to radiographic response for advanced disease. However, %RVT thresholds beyond pathologic complete response and major pathologic response (=10% RVT) have not been explored. Pathologic response was prospectively assessed in the randomized, phase 3 CheckMate 816 trial (NCT02998528), which evaluated neoadjuvant nivolumab (anti-programmed death protein 1) plus chemotherapy in patients with resectable lung cancer. RVT, regression and necrosis were quantified (0-100%) in PT and LNs using a pan-tumor scoring system and tested for association with EFS in a prespecified exploratory analysis. Regardless of LN involvement, EFS improved with 0% versus >0% RVT-PT (hazard ratio = 0.18). RVT-PT predicted EFS for nivolumab plus chemotherapy (area under the curve = 0.74); 2-year EFS rates were 90%, 60%, 57% and 39% for patients with 0-5%, >5-30%, >30-80% and >80% RVT, respectively. Each 1% RVT associated with a 0.017 hazard ratio increase for EFS. Combining pathologic response from PT and LNs helped differentiate outcomes. When compared with radiographic response and circulating tumor DNA clearance, %RVT best approximated EFS. These findings support pathologic response as an emerging survival surrogate. Further assessment of the full spectrum of %RVT in lung cancer and other tumor types is warranted. ClinicalTrials.gov registration: NCT02998528.

引用

页码：218 / +

页数：24

共 38 条

[11] Neoadjuvant PD-1 Blockade in Resectable Lung Cancer [J].

Forde, P. M. ;

Chaft, J. E. ;

Smith, K. N. ;

Anagnostou, V. ;

Cottrell, T. R. ;

Hellmann, M. D. ;

Zahurak, M. ;

Yang, S. C. ;

Jones, D. R. ;

Broderick, S. ;

Battafarano, R. J. ;

Velez, M. J. ;

Rekhtman, N. ;

Olah, Z. ;

Naidoo, J. ;

Marrone, K. A. ;

Verde, F. ;

Guo, H. ;

Zhang, J. ;

Caushi, J. X. ;

Chan, H. Y. ;

Sidhom, J. -W. ;

Scharpf, R. B. ;

White, J. ;

Gabrielson, E. ;

Wang, H. ;

Rosner, G. L. ;

Rusch, V. ;

Wolchok, J. D. ;

Merghoub, T. ;

Taube, J. M. ;

Velculescu, V. E. ;

Topalian, S. L. ;

Brahmer, J. R. ;

Pardoll, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (21) :1976-1986

[12] Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer [J].

Forde, Patrick M. ;

Spicer, Jonathan ;

Lu, Shun ;

Provencio, Mariano ;

Mitsudomi, Tetsuya ;

Awad, Mark M. ;

Felip, Enriqueta ;

Broderick, Stephen R. ;

Brahmer, Julie R. ;

Swanson, Scott J. ;

Kerr, Keith ;

Wang, Changli ;

Ciuleanu, Tudor-Eliade ;

Saylors, Gene B. ;

Tanaka, Fumihiro ;

Ito, Hiroyuki ;

Chen, Ke-Neng ;

Liberman, Moishe ;

Vokes, Everett E. ;

Taube, Janis M. ;

Dorange, Cecile ;

Cai, Junliang ;

Fiore, Joseph ;

Jarkowski, Anthony ;

Balli, David ;

Sausen, Mark ;

Pandya, Dimple ;

Calvet, Christophe Y. ;

Girard, Nicolas .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (21) :1973-1985

[13] The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer [J].

Goldstraw, Peter ;

Chansky, Kari ;

Crowley, John ;

Rami-Porta, Ramon ;

Asamura, Hisao ;

Eberhardt, Wilfried E. E. ;

Nicholson, Andrew G. ;

Groome, Patti ;

Mitchell, Alan ;

Bolejack, Vanessa .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) :39-51

[14] Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma [J].

Gross, N. D. ;

Miller, D. M. ;

Khushalani, N., I ;

Divi, V ;

Ruiz, E. S. ;

Meier, F. ;

Su, Y. B. ;

Swiecicki, P. L. ;

Atlas, J. ;

Geiger, J. L. ;

Hauschild, A. ;

Choe, J. H. ;

Hughes, B. G. M. ;

Schadendorf, D. ;

Patel, V. A. ;

Homsi, J. ;

Taube, J. M. ;

Lim, A. M. ;

Ferrarotto, R. ;

Kaufman, H. L. ;

Seebach, F. ;

Lowy, I ;

Yoo, S-Y ;

Mathias, M. ;

Fenech, K. ;

Han, H. ;

Fury, M. G. ;

Rischin, D. ;

Lipson, E. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (17) :1557-1568

[15] Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma [J].

He, Wenwu ;

Leng, Xuefeng ;

Mao, Tianqin ;

Luo, Xi ;

Zhou, Lingxiao ;

Yan, Jiaxin ;

Peng, Lin ;

Fang, Qiang ;

Liu, Guangyuan ;

Wei, Xing ;

Wang, Kangning ;

Wang, Chenghao ;

Zhang, Sha ;

Zhang, Xudong ;

Shen, Xudong ;

Huang, Depei ;

Yi, Huan ;

Bei, Ting ;

She, Xueke ;

Xiao, Wenguang ;

Han, Yongtao .

ONCOLOGIST, 2022, 27 (01) :E18-E28

[16] Time-dependent ROC curves for censored survival data and a diagnostic marker [J].

Heagerty, PJ ;

Lumley, T ;

Pepe, MS .

BIOMETRICS, 2000, 56 (02) :337-344

[17] Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint [J].

Hellmann, Matthew D. ;

Chaft, Jamie E. ;

William, William N., Jr. ;

Rusch, Valerie ;

Pisters, Katherine M. W. ;

Kalhor, Neda ;

Pataer, Apar ;

Travis, William D. ;

Swisher, Stephen G. ;

Kris, Mark G. .

LANCET ONCOLOGY, 2014, 15 (01) :E42-E50

[18]

Heymach John V., 2023, Cancer Res., V83, pCT005, DOI [DOI 10.1158/1538-7445.AM2023-CT005, 10.1158/1538-7445.AM2023-CT005]

[19] End points and United States food and drug administration approval of oncology drugs [J].

Johnson, JR ;

Williams, G ;

Pazdur, R .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) :1404-1411

[20] A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma [J].

Ju, Wu-tong ;

Xia, Rong-hui ;

Zhu, Dong-wang ;

Dou, Sheng-jin ;

Zhu, Guo-pei ;

Dong, Min-jun ;

Wang, Li-zhen ;

Sun, Qi ;

Zhao, Tong-chao ;

Zhou, Zhi-hang ;

Liang, Si-yuan ;

Huang, Ying-ying ;

Tang, Yong ;

Wu, Si-cheng ;

Xia, Jing ;

Chen, Shi-qing ;

Bai, Yue-zong ;

Li, Jiang ;

Zhu, Qi ;

Zhong, Lai-ping .

NATURE COMMUNICATIONS, 2022, 13 (01)

← 1 2 3 4 →